DK0744941T3 - Fremgangsmåde til fremstilling af findelte farmaceutiske formuleringer - Google Patents

Fremgangsmåde til fremstilling af findelte farmaceutiske formuleringer

Info

Publication number
DK0744941T3
DK0744941T3 DK95909559T DK95909559T DK0744941T3 DK 0744941 T3 DK0744941 T3 DK 0744941T3 DK 95909559 T DK95909559 T DK 95909559T DK 95909559 T DK95909559 T DK 95909559T DK 0744941 T3 DK0744941 T3 DK 0744941T3
Authority
DK
Denmark
Prior art keywords
pharmaceutical formulations
finely divided
preparing finely
divided pharmaceutical
extrusion
Prior art date
Application number
DK95909559T
Other languages
English (en)
Inventor
Pramod K Gupta
Jacqueline E Briskin
Claud Loyd
Robert W Kohler
Susan J Semla
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Lab filed Critical Abbott Lab
Application granted granted Critical
Publication of DK0744941T3 publication Critical patent/DK0744941T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
DK95909559T 1994-02-16 1995-02-14 Fremgangsmåde til fremstilling af findelte farmaceutiske formuleringer DK0744941T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19702594A 1994-02-16 1994-02-16
PCT/US1995/001943 WO1995022319A1 (en) 1994-02-16 1995-02-14 Process for preparing fine particle pharmaceutical formulations

Publications (1)

Publication Number Publication Date
DK0744941T3 true DK0744941T3 (da) 2003-09-29

Family

ID=22727703

Family Applications (1)

Application Number Title Priority Date Filing Date
DK95909559T DK0744941T3 (da) 1994-02-16 1995-02-14 Fremgangsmåde til fremstilling af findelte farmaceutiske formuleringer

Country Status (11)

Country Link
US (1) US6063313A (da)
EP (1) EP0744941B1 (da)
JP (1) JP4040084B2 (da)
AT (1) ATE241962T1 (da)
CA (1) CA2182282C (da)
DE (1) DE69530973T2 (da)
DK (1) DK0744941T3 (da)
ES (1) ES2199981T3 (da)
MX (1) MX9603480A (da)
PT (1) PT744941E (da)
WO (1) WO1995022319A1 (da)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19531277A1 (de) * 1995-08-25 1997-02-27 Basf Ag Verwendung von Lipiden als Hilfsmittel bei der Herstellung von festen Arzneiformen nach dem Schmelzextrusionsverfahren
EP1014941B2 (en) 1996-06-26 2017-05-17 The Board Of Regents, The University Of Texas System Hot-melt extrudable pharmaceutical formulation
US6139872A (en) * 1996-08-14 2000-10-31 Henkel Corporation Method of producing a vitamin product
FR2753904B1 (fr) * 1996-10-01 1998-10-30 Gattefosse Ets Sa Composition pharmaceutique a liberation modifiee de principe actif, comportant une matrice, et procede de fabrication
IT1298574B1 (it) * 1998-02-06 2000-01-12 Vectorpharma Int Composizioni farmaceutiche in forma di microparticelle a base polimerica ottenute mediante estrusione e sferonizzazione
DK1073513T3 (da) * 1998-04-24 2003-12-22 Basf Corp Forbedret ekstruderingsproces
JP2000128774A (ja) * 1998-10-26 2000-05-09 Tanabe Seiyaku Co Ltd 薬物を含有する球形微粒子の製法
SI20150A (sl) * 1999-02-19 2000-08-31 Lek, Tovarna Farmacevtskih In Direktno stisljivi matriks za nadzorovano sproščanje celodnevne doze klaritromicina
US7658938B2 (en) 1999-02-22 2010-02-09 Merrion Reasearch III Limited Solid oral dosage form containing an enhancer
US6365216B1 (en) 1999-03-26 2002-04-02 The Nutrasweet Company Particles of N-[N-(3,3-dimethylbutyl)-L-α-aspartyl]-L-phenylalanine 1-methyl ester
DE19916383A1 (de) * 1999-03-31 2000-10-05 Schering Ag Pharmazeutische Zusammensetzung mit einem Extrusionsstoff
WO2001034119A2 (en) 1999-11-12 2001-05-17 Abbott Laboratories Inhibitors of crystallization in a solid dispersion
DK1267840T3 (da) * 2000-03-28 2009-09-07 Sandoz Ag Granulerede partikler med maskeret smag
DE10026698A1 (de) 2000-05-30 2001-12-06 Basf Ag Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung
CA2423172A1 (en) * 2000-09-22 2002-03-28 Galephar M/F Sustained release composition containing clarithromycin
FR2816507B1 (fr) 2000-11-16 2003-02-28 Ethypharm Lab Prod Ethiques Microgranules a base de principe actif, procede de fabrication et compositons pharmaceutiques integrant lesdits microgranules
ITRN20000051A1 (it) 2000-12-22 2002-06-22 Ascor Chimici Srl Metodo e apparecchiatura per formare sferule composite contenenti principi attivi del tipo farmaceutico e/o integratori alimentari o cosmeti
US20030176379A1 (en) 2001-05-11 2003-09-18 Raoof Araz A. Antisense permeation enhancers
US20030203019A1 (en) * 2002-04-30 2003-10-30 Cornelius John Mark Coated conditioners for use in foods and pharmaceuticals
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
AU2004212976A1 (en) * 2003-02-19 2004-09-02 Biovail Laboratories Inc. Rapid absorption selective 5-HT agonist formulations
WO2004112711A2 (en) 2003-06-16 2004-12-29 Andrx Pharmaceuticals, Llc Oral extended-release composition
TWI357815B (en) * 2003-06-27 2012-02-11 Euro Celtique Sa Multiparticulates
US20060165790A1 (en) * 2003-06-27 2006-07-27 Malcolm Walden Multiparticulates
DE102004032051A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten, festen Darreichungsform
DE10361596A1 (de) 2003-12-24 2005-09-29 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
DE10336400A1 (de) 2003-08-06 2005-03-24 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
US20070048228A1 (en) 2003-08-06 2007-03-01 Elisabeth Arkenau-Maric Abuse-proofed dosage form
DE102005005446A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Bruchfeste Darreichungsformen mit retardierter Freisetzung
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
WO2005023221A1 (en) * 2003-09-05 2005-03-17 Ranbaxy Laboratories Limited Clarithromycin formulations having improved biovailability
GB2411355B (en) 2004-02-27 2006-02-22 Niche Generics Ltd Pharmaceutical composition
US7491263B2 (en) * 2004-04-05 2009-02-17 Technology Innovation, Llc Storage assembly
DE102004032049A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
GB2418854B (en) 2004-08-31 2009-12-23 Euro Celtique Sa Multiparticulates
DE102005005449A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
DE102006006532B4 (de) * 2006-02-10 2007-11-08 Biogenerics Pharma Gmbh Pharmazeutische Zubereitung
BRPI0710503A2 (pt) 2006-04-07 2011-08-16 Merrion Res Iii Ltd uso de uma composição farmacêutica, composição farmacêutica, e, forma de dosagem oral
SA07280459B1 (ar) 2006-08-25 2011-07-20 بيورديو فارما إل. بي. أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني
US20080131504A1 (en) * 2006-12-01 2008-06-05 Mission Pharmacal Co. Short Term Slow Release Drug Delivery System
KR101616246B1 (ko) 2008-01-25 2016-05-02 그뤼넨탈 게엠베하 약제학적 투여형
MX2010012201A (es) 2008-05-07 2011-05-30 Merrion Res Iii Ltd Composiciones de péptidos y procedimientos de preparación de las mismas.
MX2010012039A (es) 2008-05-09 2010-11-30 Gruenenthal Gmbh Proceso para la preparacion de una formulacion de polvo intermedia y una forma de dosificacion solida final bajo el uso de un paso de congelacion por rocio.
RU2015138422A (ru) 2009-07-22 2018-12-25 Грюненталь Гмбх Стабильная при окислении, прочная на излом лекарственная форма
MX2012000317A (es) 2009-07-22 2012-02-08 Gruenenthal Gmbh Forma de dosificacion de liberacion controlada extruida por fusion en caliente.
EP2516494B1 (en) * 2009-12-23 2016-06-01 Essilor International (Compagnie Générale D'Optique) Method of converting a polymerizable composition into thermoplastic polyurethane of improved yellowness index and article obtained by this method
WO2011120033A1 (en) 2010-03-26 2011-09-29 Merrion Research Iii Limited Pharmaceutical compositions of selective factor xa inhibitors for oral administration
CA2808219C (en) 2010-09-02 2019-05-14 Gruenenthal Gmbh Tamper resistant dosage form comprising inorganic salt
ES2487244T3 (es) 2010-09-02 2014-08-20 Grünenthal GmbH Forma de dosificación resistente a la manipulación que comprende un polímero aniónico
EP2661273A4 (en) 2011-01-07 2014-06-04 Merrion Res Iii Ltd IRON PHARMACEUTICAL COMPOSITIONS FOR ORAL ADMINISTRATION
AU2012292418B2 (en) 2011-07-29 2017-02-16 Grunenthal Gmbh Tamper-resistant tablet providing immediate drug release
CA2839123A1 (en) 2011-07-29 2013-02-07 Grunenthal Gmbh Tamper-resistant tablet providing immediate drug release
MX356421B (es) 2012-02-28 2018-05-29 Gruenenthal Gmbh Forma de dosificacion resistente a la manipulacion indebida que comprende un compuesto farmacologicamente activo y un polimero anionico.
CN104394851B (zh) 2012-04-18 2017-12-01 格吕伦塔尔有限公司 抗篡改和抗剂量‑倾泻药物剂型
US10064945B2 (en) 2012-05-11 2018-09-04 Gruenenthal Gmbh Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
CA2907950A1 (en) 2013-05-29 2014-12-04 Grunenthal Gmbh Tamper-resistant dosage form containing one or more particles
AR096438A1 (es) 2013-05-29 2015-12-30 Gruenenthal Gmbh Forma de dosificación resistente al uso indebido con perfil de liberación bimodal, proceso
BR112016000194A8 (pt) 2013-07-12 2019-12-31 Gruenenthal Gmbh forma de dosagem resistente à violação contendo o polímero de acetato de etileno-vinila
CN105934241B (zh) 2013-11-26 2020-06-05 格吕伦塔尔有限公司 通过低温研磨制备粉末状药物组合物
WO2015173195A1 (en) 2014-05-12 2015-11-19 Grünenthal GmbH Tamper resistant immediate release capsule formulation comprising tapentadol
JP2017516789A (ja) 2014-05-26 2017-06-22 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング エタノール過量放出に対して防護されている多粒子
EP3250191B1 (en) 2015-01-29 2024-01-17 Novo Nordisk A/S Tablets comprising glp-1 agonist and enteric coating
EP3285745A1 (en) 2015-04-24 2018-02-28 Grünenthal GmbH Tamper-resistant dosage form with immediate release and resistance against solvent extraction
CA2998259A1 (en) 2015-09-10 2017-03-16 Grunenthal Gmbh Protecting oral overdose with abuse deterrent immediate release formulations

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB757165A (en) * 1953-10-30 1956-09-12 Abbott Lab Compositions of erythromycin for combating bacterial infections
US4374082A (en) * 1981-08-18 1983-02-15 Richard Hochschild Method for making a pharmaceutical and/or nutritional dosage form
FR2581541B1 (fr) * 1985-05-09 1988-05-20 Rhone Poulenc Sante Nouvelles compositions pharmaceutiques permettant la liberation prolongee d'un principe actif et leur procede de preparation
DE3524572A1 (de) * 1985-07-10 1987-01-15 Thomae Gmbh Dr K Feste arzneimittelformen zur peroralen anwendung enthaltend 9-deoxo-11-deoxy-9,11-(imino(2-(2-methoxyethoxy)ethyliden)-oxy)-(9s)-erythromycin und verfahren zu ihrer herstellung
US4686231A (en) * 1985-12-12 1987-08-11 Smithkline Beckman Corporation Inhibition of 5-lipoxygenase products
US4800087A (en) * 1986-11-24 1989-01-24 Mehta Atul M Taste-masked pharmaceutical compositions
IL84944A (en) * 1987-01-19 1992-02-16 Ici Plc Pharmaceutical compositions containing 1,2-dihydro-3h-indazolone derivatives,some new such compounds and their preparation
IT1226549B (it) * 1988-07-12 1991-01-24 Resa Farma Composizioni farmaceutiche ad attivita' analgesica ed antiinfiammatoria per uso orale, dotate di ottima palatabilita' ed esenti da effetti irritanti sulle mucose.
US5126145A (en) * 1989-04-13 1992-06-30 Upsher Smith Laboratories Inc Controlled release tablet containing water soluble medicament
US5002774A (en) * 1989-06-08 1991-03-26 Erbamont, Inc. Sustained release pharmaceutical tablet
US5169645A (en) * 1989-10-31 1992-12-08 Duquesne University Of The Holy Ghost Directly compressible granules having improved flow properties
FR2657257B1 (fr) * 1990-01-19 1994-09-02 Rhone Poulenc Sante Procede de preparation de medicaments sous forme de perles.
FR2663818B1 (fr) * 1990-06-29 1993-07-09 Rhone Poulenc Nutrition Animale Procede de preparation de granules de principes actifs par extrusion.
JP3265680B2 (ja) * 1992-03-12 2002-03-11 大正製薬株式会社 経口製剤用組成物
US5292900A (en) * 1992-12-18 1994-03-08 Abbott Laboratories O-substituted N-hydroxyurea derivatives

Also Published As

Publication number Publication date
CA2182282C (en) 2006-04-18
ATE241962T1 (de) 2003-06-15
CA2182282A1 (en) 1995-08-24
JPH09509176A (ja) 1997-09-16
EP0744941B1 (en) 2003-06-04
US6063313A (en) 2000-05-16
DE69530973D1 (de) 2003-07-10
ES2199981T3 (es) 2004-03-01
MX9603480A (es) 1997-12-31
JP4040084B2 (ja) 2008-01-30
WO1995022319A1 (en) 1995-08-24
EP0744941A1 (en) 1996-12-04
DE69530973T2 (de) 2004-05-19
PT744941E (pt) 2003-10-31

Similar Documents

Publication Publication Date Title
DK0744941T3 (da) Fremgangsmåde til fremstilling af findelte farmaceutiske formuleringer
ES524518A0 (es) Un procedimiento para preparar un agente anti-inflamatorio
MX9602515A (es) Procedimiento para preparar formas de dosis farmaceuticas de substancias hidrofobicas.
AR011080A1 (es) Composicion en polvo seco, proceso para su preparacion y uso de dicha composicion para la fabricacion del medicamento
LV12231A (lv) Dispersa makromolekulu kompozicija
NO990790L (no) Blandinger omfattende mikropartikler av vann-ul°selige forbindelser og fremgangsmÕte for fremstilling av samme
ZA200409395B (en) Method for the production of crystals, crystals obtained by said method, and use thereof in pharmaceutical formulations.
UA42795C2 (uk) Протизапальний засіб для зовнішнього застосування, що містить німесулід, і спосіб його одержання
ATE269057T1 (de) Arzneizubereitungen und deren herstellungsverfahren
NO303715B1 (no) Stabilt, vandig apparat
ZA200409401B (en) Method for producing steroid crystals, crystals obtained by said method and their use in pharmaceutical formulations.
YU10599A (sh) Amorfni benzotiofeni, postupak dobijanja istih i njihova farmaceutska formulacija
HUT55004A (en) Process for producing 1,3-disubstituted 5-aryl-carbamoyl-4(6)-oxo-6(4)-oxido-pyrimidine-betaine derivatives and anthelmintic compositions containing them as active components
ATE1880T1 (de) Stabile valepotriat-zubereitungen und verfahren zu deren herstellung.
HUP9702480A3 (en) New polymorphous form of doxazosin-mesylate (form. i.), process for it's preparation and pharmaceutical compositions containing the same
DE69431662D1 (de) Stabilisierte tablettenformulierung
HUP9702479A3 (en) New polymorphous form of doxazosin-mesylate (form ii.), process for it's preparation and pharmaceutical compositions containing the same
NL194271B (nl) Werkwijze voor de bereiding van de verbinding L-5-(2-acetoxy-propionylamino)-2,4,6-trijood-isoftaalzuur-bis-(1,3- -dihydropropylamide).
HUT45502A (en) Process for producing new 2,6-diamino-3-(halogen-benzyl)-pyridines and pharmaceutics comprising the same as active ingredient
AU1167097A (en) 18-methyl 16-methylene 19-nor pregnane derivatives as progestins, pharmaceutical compositions containing them and process for the preparation thereof
FR2758325B1 (fr) Composes tetracycliques aromatiques de type retinoide leur procede de preparation et leur utilisation pour la fabrication de compositions pharmaceutiques et cosmetiques
HUP9702465A3 (en) Epimers of (22rs)-n-(1,1,1,-trifluoro-2-phenylprop-2-yl)-3-oxo-4-aza-5alfa-androst-1-ene-17beta-carboxamide, process for producing them and pharmaceutical compositions containing the same
BG101071A (en) Novel antitumor and antileukemia substances, preparation thereof and pharmaceutical compositions containing same